Business Context and Reporting Period
Company: Immuron Ltd (Foreign Private Issuer)
Filing Type: Form 6-K
Reporting Period: Half-year ended February 25, 2022 (Announcement date)
Context: This filing serves as a conduit to the U.S. Securities and Exchange Commission for a "Half Yearly Report and Accounts" originally published to the Australian Securities Exchange (ASX). The document itself is a cover sheet and does not contain the detailed financial statements, which are attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a Form 6-K cover sheet and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Ratios
Note: Investors must refer to the attached Exhibit 99.1 ("Half Yearly Report and Accounts") for these figures.
Material Changes
The filing text does not provide comparative financial data or describe material changes versus prior periods. It only confirms the publication of the half-yearly report.
Guidance, Outlook, and Risks
Management Commentary: None provided in the cover text.
Guidance/Outlook: Not stated in the provided text.
Risks and Contingencies: Not stated in the provided text.
Unusual Items: None identified in the cover text.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Half Yearly Report and Accounts) to obtain actual financial performance data.
- Confirm the specific half-year end date within the attached report to ensure accurate period comparison.
- Review the attached report for any updates on clinical trial progress or regulatory milestones, as Immuron is a biopharmaceutical company.
- Check for any subsequent announcements regarding the financial results if the attached exhibit is not immediately accessible.